The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Challenges & opportunities in bringing bispecifics & CAR T-cells into the community
Tara Graff, DO, Mission Cancer and Blood, Des Moines, IA, comments on the challenges and opportunities presented by novel therapies, namely bispecific antibodies and CAR T-cells, in the community setting. Dr Graff highlights the need for education on managing unique side effect profiles and selecting patients for these therapies. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
